Editorial: Tamoxifen and the factor v leiden mutation

Journal of the National Cancer Institute

Volumn 102, Issue 13, 2010, Pages 918-919

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BLOOD CLOTTING FACTOR 5; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; EDITORIAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; GENETICS; MUTATION; NOTE; PREVALENCE; RISK FACTOR;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FACTOR V; FEMALE; HUMANS; MUTATION; PREVALENCE; RISK FACTORS; TAMOXIFEN; THROMBOEMBOLISM;

EID: 77954718073     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq225     Document Type: Editorial

References (14)

1. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300.
2. Price DT, Ridker PM. Factor V Leiden mutation and the risks for throm-boembolic disease: a clinical perspective. Ann Intern Med. 1997;127(10): 895-903.
3. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132(9): 689-696.
4. Cuzick J, Forbes J, Edwards R, et al. First results from the IBIS Breast Cancer Prevention Trial. Lancet. 2002;360(9336):817-824.
5. Fisher B, Costantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
6. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003;21(19):3588-3593.
7. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-3703.
8. Abramson N, Constantino JP, Garber JE, et al. Effect of Factor V Leiden and prothrombin G20210-A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst. 2006;98(13):904-910.
9. Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102(13):942-949.
10. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
11. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
12. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
13. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer [published online ahead of print May 6, 2010]. Cancer Prev Res. 2010.
14. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8(9):1377-1385.